首页> 外文期刊>Bone marrow transplantation >Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation.
【24h】

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation.

机译:在异基因造血干细胞移植中,应该使用理想的体重而不是实际的体重来计算细胞剂量。

获取原文
获取原文并翻译 | 示例
       

摘要

Whether the CD34+ and CD3+ cell doses in allogeneic HSCT should be estimated using actual (ABW) or ideal (IBW) body weight has never been definitively determined. We have shown that CD34+ cell doses based upon IBW are better predictive of engraftment after autologous and allogeneic HSCT. Sixty-three patients undergoing reduced-intensity HSCT after a uniform preparative regimen were evaluated to determine the effect of cell dose. ABW and IBW were 45-147 kg (median 79) and 52-85 kg (median 67) respectively. The ABW-IBW difference was -24% to +133% (median +16%); nine patients were >5% underweight and 41 were >5% overweight. The CD34+ cell dose (10(6)/kg) was 1.4-11.8 (median 5) by IBW and 1.2-9.3 (median 4.5) by ABW. The CD3+ cell dose (10(8)/kg) was 0.9-14.9 (median 3) by IBW and 0.7-19.7 (median 2.7) by ABW. While CD34+ and CD3+ cell doses based upon IBW were found to affect transplant-related mortality, and disease-free and overall survival significantly, those based on ABW were either not predictive of outcome or the differences were of borderline significance. We suggest using IBW rather than ABW to calculate cell doses for HSCT; for statistical analyses and for clinical practice if a specific cell dose is being targeted.
机译:尚未明确确定同种异体HSCT中CD34 +和CD3 +细胞的剂量应使用实际(ABW)或理想(IBW)体重估算。我们已经显示,基于IBW的CD34 +细胞剂量可以更好地预测自体和异体HSCT后的植入。对63例接受统一制备方案后接受降低强度HSCT的患者进行评估,以确定细胞剂量的影响。 ABW和IBW分别为45-147 kg(中位数79)和52-85 kg(中位数67)。 ABW-IBW差异为-24%至+ 133%(中位数+ 16%); 9名患者的体重不足> 5%,而41%的体重超过5%。 IBW的CD34 +细胞剂量(10(6)/ kg)为1.4-11.8(中位数5),ABW为1.2-9.3(中位数4.5)。 IBW的CD3 +细胞剂量(10(8)/ kg)为0.9-14.9(中位数3),ABW为0.7-19.7(中位数2.7)。虽然发现基于IBW的CD34 +和CD3 +细胞剂量会显着影响与移植相关的死亡率,并且无病生存期和总体生存期显着,但基于ABW的剂量要么不能预测结果,要么差异具有临界意义。我们建议使用IBW而非ABW来计算HSCT的细胞剂量;用于统计分析和临床实践(如果要针对特定​​的细胞剂量)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号